Literature DB >> 32389130

Sustainability of healthcare systems in Asia: exploring the roles of horizon scanning and reassessment in the health technology assessment landscape.

Linda Mundy1, Rebecca Trowman2, Brendon Kearney3.   

Abstract

OBJECTIVES: The 2019 Health Technology Assessment International (HTAi) Asia Policy Forum (HAPF) discussed the role of horizon scanning (HS) and health technology reassessment (HTR) in supporting sustainable healthcare in Asia.
METHODS: Discussions and presentations at the 2019 HAPF, informed by a literature review, results of a premeeting survey, and case studies of HTA agencies from the region form the basis of this paper.
RESULTS: Five of the fourteen HTA agencies surveyed have established or are developing HS systems (HSSs), and six reported some experience with HTR. Although there were many differences in the respective HSSs, all were proactive and identified technologies within a 1-3-year time horizon. Commonalities included the criteria used to prioritize the technologies including burden and rarity of the disease, and cost to the health system and patients. Experience in HTR was not as extensive with most HTR activity being conducted on an ad hoc basis. Challenges for both HS and HTR include a lack of HTA capacity and good quality data, as well as a need for transparency and collaboration with industry.
CONCLUSIONS: With developing universal health care and HTA capacity in many countries in Asia, HS and HTR are in their infancy. Whilst several countries in the region are experienced in all facets of HTA, other countries are developing their HTA skill base. As such, there was a clear appetite for setting up a collaborative network in the Asia region to facilitate information sharing around HTA activities, and more specifically, HS and HTR methodologies, experiences, and assessments.

Entities:  

Keywords:  Decision making; Emerging health technology; Health; Health policy; Health technology reassessment; Horizon scanning; Technology assessment

Mesh:

Year:  2020        PMID: 32389130     DOI: 10.1017/S0266462320000252

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  2 in total

1.  Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.

Authors:  Wei Fang Dai; Erica Craig; Brent Fraser; Alex Chambers; Helen Mai; M Bryson Brown; Craig C Earle; William K Evans; Marc Geirnaert; Marianne Taylor; Maureen Trudeau; Daniel Sperber; Jaclyn M Beca; Avram Denburg; Rebecca E Mercer; Ambica Parmar; Mina Tadrous; Pam Takhar; Kelvin K W Chan
Journal:  Curr Oncol       Date:  2021-11-12       Impact factor: 3.677

2.  Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".

Authors:  Unni Gopinathan; Trygve Ottersen; Pascale-Renée Cyr; Kalipso Chalkidou
Journal:  Int J Health Policy Manag       Date:  2021-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.